Experienced in Prolymphocytic Leukemia

Dr. Timothy Pardee

Hematology
North Carolina Baptist Hospital
1 Medical Ctr Blvd, 
Winston Salem, NC 
Experienced in Prolymphocytic Leukemia
North Carolina Baptist Hospital
1 Medical Ctr Blvd, 
Winston Salem, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Timothy Pardee is a Hematologist in Winston Salem, North Carolina. Dr. Pardee is rated as an Experienced provider by MediFind in the treatment of Prolymphocytic Leukemia. His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Acute Myeloblastic Leukemia without Maturation, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 60 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Licenses
Internal Medicine in NC
Hospital Affiliations
North Carolina Baptist Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
AmeriHealth
  • EPO
  • HMO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

North Carolina Baptist Hospital
1 Medical Ctr Blvd, Winston Salem, NC 27103

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Phase 3 Randomized Trial of DFP-10917 vs Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High & Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, Third, or Fourth Salvage
Phase 3 Randomized Trial of DFP-10917 vs Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High & Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, Third, or Fourth Salvage
Enrollment Status: Terminated
Publish Date: January 22, 2026
Intervention Type: Drug
Study Drugs: DFP-10917, Cytarabine, Azacitidine, Decitabine, Mitoxantrone, Etoposide, Fludarabine, Idarubicin, Venetoclax, Cladribine
Study Phase: Phase 3
A Pilot Study of CPI-613 in Patients With Myelodysplastic Syndrome Who Have Failed Previous Therapy
A Pilot Study of CPI-613 in Patients With Myelodysplastic Syndrome Who Have Failed Previous Therapy
Enrollment Status: Terminated
Publish Date: October 17, 2024
Intervention Type: Drug
Study Phase: Phase 2
An Open Label Study to Evaluate the Feasibility of CPI-613 Given With High Dose Cytarabine and Mitoxantrone in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
An Open Label Study to Evaluate the Feasibility of CPI-613 Given With High Dose Cytarabine and Mitoxantrone in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Procedure, Drug
Study Drugs: 6,8-Bis(benzylthio)octanoic Acid, Cytarabine, Mitoxantrone
Study Phase: Phase 1
A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered With Chemotherapy Versus Chemotherapy Alone in Patients With Relapsed/Refractory Acute Myeloid Leukemia
A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered With Chemotherapy Versus Chemotherapy Alone in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Enrollment Status: Terminated
Publish Date: July 29, 2024
Intervention Type: Drug
Study Drug: Uproleselan
Study Phase: Phase 3
A Study of the Metabolic Changes in Leukemia Cells Following Treatment in AML Patients
A Study of the Metabolic Changes in Leukemia Cells Following Treatment in AML Patients
Enrollment Status: Completed
Publish Date: October 20, 2022
Intervention Type: Other
Investigating the Prognostic Importance of Bioelectrical Impedance Phase Angle in Adults Treated for Newly Diagnosed Acute Leukemia
Investigating the Prognostic Importance of Bioelectrical Impedance Phase Angle in Adults Treated for Newly Diagnosed Acute Leukemia
Enrollment Status: Completed
Publish Date: August 13, 2020
Intervention Type: Procedure
Study Phase: Not Applicable
An Open Label, Phase II Study of the Feasibility and Efficacy of Vincristine Sulfate Liposome Injection in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
An Open Label, Phase II Study of the Feasibility and Efficacy of Vincristine Sulfate Liposome Injection in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Enrollment Status: Terminated
Publish Date: August 14, 2019
Intervention Type: Drug, Other
Study Phase: Phase 2
A Phase 1/2 Study of Vadastuximab Talirine (SGN-CD33A) in Combination With Azacitidine in Patients With Previously Untreated International Prognostic Scoring System (IPSS) Intermediate-2 or High Risk Myelodysplastic Syndrome (MDS)
A Phase 1/2 Study of Vadastuximab Talirine (SGN-CD33A) in Combination With Azacitidine in Patients With Previously Untreated International Prognostic Scoring System (IPSS) Intermediate-2 or High Risk Myelodysplastic Syndrome (MDS)
Enrollment Status: Terminated
Publish Date: February 12, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 7 Less Clinical Trials

60 Total Publications

AML Disparities Across Racial Ancestry Groups: A Spotlight on the NPM1 Mutations.
AML Disparities Across Racial Ancestry Groups: A Spotlight on the NPM1 Mutations.
Journal: International journal of molecular sciences
Published: November 14, 2025
Similar Doctors
Susan Hines
Distinguished in Prolymphocytic Leukemia
Dr. Susan Hines
Oncology | Hematology
Distinguished in Prolymphocytic Leukemia
Dr. Susan Hines
Oncology | Hematology

Novant Health Cancer Institute - Mt. Airy

1908 Caudle Dr, Ste 200, 
Mount Airy, NC 
 (33.6 miles away)
336-783-6935
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Susan Hines is a Hematologist and an Oncologist in Mount Airy, North Carolina. Dr. Hines is rated as a Distinguished provider by MediFind in the treatment of Prolymphocytic Leukemia. Her top areas of expertise are Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET), Paget Disease of the Breast, Angiosarcoma, and Bone Marrow Aspiration.

Experienced in Prolymphocytic Leukemia
Dr. Rupali Roy
Hematology
Experienced in Prolymphocytic Leukemia
Dr. Rupali Roy
Hematology

North Carolina Baptist Hospital

1 Medical Ctr Blvd, 
Winston Salem, NC 
 (0.2 miles away)
336-716-2011
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Rupali Roy is a Hematologist in Winston Salem, North Carolina. Dr. Roy is rated as a Distinguished provider by MediFind in the treatment of Prolymphocytic Leukemia. Her top areas of expertise are Acute Myeloid Leukemia (AML), Chronic Myelogenous Leukemia (CML), Polycythemia Vera, Acute Myeloblastic Leukemia without Maturation, and Bone Marrow Aspiration.

Franklin Chen
Experienced in Prolymphocytic Leukemia
Dr. Franklin Chen
Hematology
Experienced in Prolymphocytic Leukemia
Dr. Franklin Chen
Hematology

Novant Health Cancer Institute - Forsyth (Cellular Therapy & Apheresis)

1010 Bethesda Ct, 
Winston Salem, NC 
 (1.6 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Franklin Chen is a Hematologist in Winston Salem, North Carolina. Dr. Chen is rated as an Advanced provider by MediFind in the treatment of Prolymphocytic Leukemia. His top areas of expertise are Colorectal Cancer, Neuroendocrine Tumor, Familial Colorectal Cancer, Bone Marrow Aspiration, and Bone Marrow Transplant.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Pardee's expertise for a condition
ConditionClose
View All 13 Advanced Conditions
View All 27 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile